SCHEMBL9942910

SCHEMBL9942910

CN(C(=O)C(=O)N1CC[C@@H](F)C1)C12CCC(F)(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.48
KCNH2 Q12809 1/20 0.47
KCNE1 P15382 1/20 0.36
CCR1 P32246 1/20 0.36
KCNQ1 P51787 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
CALCA P06881 1/20 0.34
ERCC1 P07992 1/20 0.33
FEN1 P39748 1/20 0.33
ERCC4 Q92889 1/20 0.33
GAA P10253 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
MAPT P10636 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
LIPG Q9Y5X9 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904916 0.91 CYP2C9 (0.40) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL9905090 0.91 CYP2C9 (0.39) CYP2C9KCNH2
SCHEMBL52047 0.90 CYP2C9 (0.49) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL9904561 0.86 CYP2C9 (0.55) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL14119297 0.83 KCNH2 (0.42) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL52108 0.82 CYP2C9 (0.54) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL10144275 0.81 CYP2C9 (0.49) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL52304 0.81 CYP2C9 (0.40) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL418770 0.81 CYP2C9 (0.49) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL420090 0.79 CYP2C9 (0.55) CYP2C9KCNH2KCNE1CCR1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
WO-2012078834-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309698-A1 HIV Integrase Inhibitors DNTT, POLB, UNG CYP2C9 602/4885KCNH2 3969/4885KCNE1 4273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.